Skip to content
Screener

Allogene Therapeutics ALLO Q4 2025 Annual earnings

Reported March 12, 2026 · After market close

Revenue-
EPS-$0.17Beat by $0.08
EPS estimate-$0.25

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$2.5K
EPS estimate-$0.13

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$42.4M+29.9%
Net income-$38.8M+35.3%
EPS (diluted)-$0.17+39.3%

Balance sheet

See full
Cash & equivalents$62.0M-27.5%
Total debt$83.3M-8.3%
Total equity$292.5M-30.7%
Total assets$415.9M-24.2%

Cash flow

See full
Operating cash flow-$27.6M+24.8%
CapEx--100%
Free cash flow-$27.6M+25.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$307.88M-31.1%
Enterprise value$329.15M-27.2%

Returns & leverage

See full
Return on equity-53.4%-1.6pp
Debt / equity0.3×+0.1×
Current ratio7.9×-0.6×

Segments

By segment

See full
Reportable Segment-—

FAQ

When did Allogene Therapeutics report Q4 2025 earnings?
Allogene Therapeutics (ALLO) reported Q4 2025 earnings on March 12, 2026 after market close.
What were Allogene Therapeutics's Q4 2025 revenue and EPS?
Allogene Therapeutics reported revenue of - and eps of $-0.17 for Q4 2025.
Did Allogene Therapeutics beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.25 by $0.08.
How did Allogene Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $22.0K a year earlier and eps grew 39.3% from $-0.28.
Where can I find Allogene Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001628280-26-017230) and the 10-K periodic report (0001628280-26-017242) directly on SEC EDGAR. The filing index links above go to sec.gov.